Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Small-particle versus large-particle budesonide for uncontrolled asthma
ACTRN12616000112460Phase 3Not yet recruiting
- Sponsor
- Woolcock Institute of Medical Research
- Start
- Feb 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of budesonide in asthma (2 arms), sponsored by Woolcock Institute of Medical Research. Primary endpoint: Change in small airway function. Planned start Feb 2016; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on ACTRN12616000112460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000112460.